GlaxoSmithKline targets growth across units, scraps ViiV listing
GlaxoSmithKline laid out growth targets for its biggest businesses on Wednesday, hoping to convince investors that focusing on consumer health and vaccines would return the drugmaker to long-term growth.
May 06, 2015, 17:28 PM IST
Lupin gets USFDA approval for HIV drug
Drug major Lupin has received US health regulator's approval to market a generic version of ViiV Healthcare's Epivir Tablets, used in treating HIV infection, in the American market.
Dec 26, 2014, 16:04 PM IST